MusclePharm Avanti P/E
Cos'è Avanti P/E di MusclePharm?
Avanti P/E di MusclePharm Corp. è -0.74
Qual è la definizione di Avanti P/E?
Il rapporto prezzo / utili a termine è il rapporto tra il prezzo delle azioni di una società e l'utile stimato per azione della società per i prossimi dodici mesi.
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
Avanti P/E di aziende nel Consumer Staples settore su OTC rispetto a MusclePharm
Cosa fa MusclePharm?
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.
Aziende con avanti p/e simili a MusclePharm
- Energous Corp ha Avanti P/E di -0.77
- Interpace Biosciences Inc ha Avanti P/E di -0.76
- Milestone Pharmaceuticals Inc ha Avanti P/E di -0.76
- Sonnet BioTherapeutics Inc ha Avanti P/E di -0.75
- Aspen Inc ha Avanti P/E di -0.75
- Aclaris Therapeutics Inc ha Avanti P/E di -0.74
- MusclePharm ha Avanti P/E di -0.74
- Karyopharm Therapeutics Inc ha Avanti P/E di -0.73
- Cellectar Biosciences Inc ha Avanti P/E di -0.73
- Surface Oncology Inc ha Avanti P/E di -0.73
- Mersana Therapeutics Inc ha Avanti P/E di -0.72
- MJardin ha Avanti P/E di -0.71
- FibroGen Inc ha Avanti P/E di -0.70